PE Hub -- Ambrx Inc., a La Jolla, Calif.-based developer of genetically-engineered protein therapeutics, has raised $10 million in new equity funding, according to a regulatory filing. The company previously raised around $70 million from firms like 5AM Ventures, Aravis Ventures, CMEA Capital, Maverick Capital, Versant Ventures and Tavistock Life Sciences. www.ambrx.com
